WallStreetZenWallStreetZen

NASDAQ: IMAB
I Mab Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IMAB

Based on 3 analysts offering 12 month price targets for I Mab

Min Forecast
$5.00+134.74%
Avg Forecast
$6.33+197.32%
Max Forecast
$7.00+228.64%

Should I buy or sell IMAB stock?

Based on 3 analysts offering ratings for I Mab.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their IMAB stock forecasts and price targets.

IMAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-09
lockedlocked$00.00+00.00%2025-07-09
lockedlocked$00.00+00.00%2025-04-04

1 of 1

Forecast return on equity

Is IMAB forecast to generate an efficient return?

Company
-71.91%
Industry
167.47%
Market
90.43%
IMAB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMAB forecast to generate an efficient return on assets?

Company
-68.27%
Industry
44.43%
IMAB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMAB earnings per share forecast

What is IMAB's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.44
Avg 2 year Forecast
-$0.73
Avg 3 year Forecast
-$0.78

IMAB revenue forecast

What is IMAB's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$22.7M
Avg 2 year Forecast
$50.2M
Avg 3 year Forecast
$134.2M

IMAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMAB$2.13$6.33+197.32%Buy
KYTX$4.03$12.50+210.17%Strong Buy
ACOG$10.82$20.00+84.93%Buy
LIMN$6.65N/AN/A
ENGN$3.31$22.00+564.65%Buy
View Top Biotech Stocks

I Mab Stock Forecast FAQ

Is I Mab Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: IMAB) stock is to Buy IMAB stock.

Out of 3 analysts, 0 (0%) are recommending IMAB as a Strong Buy, 3 (100%) are recommending IMAB as a Buy, 0 (0%) are recommending IMAB as a Hold, 0 (0%) are recommending IMAB as a Sell, and 0 (0%) are recommending IMAB as a Strong Sell.

If you're new to stock investing, here's how to buy I Mab stock.

What is IMAB's earnings growth forecast for 2025-2027?

(NASDAQ: IMAB) I Mab's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.82%.

I Mab's earnings in 2025 is -$7,577,000.On average, 3 Wall Street analysts forecast IMAB's earnings for 2025 to be -$81,959,630, with the lowest IMAB earnings forecast at -$114,484,485, and the highest IMAB earnings forecast at -$60,057,435. On average, 3 Wall Street analysts forecast IMAB's earnings for 2026 to be -$137,625,365, with the lowest IMAB earnings forecast at -$163,281,150, and the highest IMAB earnings forecast at -$121,991,664.

In 2027, IMAB is forecast to generate -$146,389,997 in earnings, with the lowest earnings forecast at -$182,049,099 and the highest earnings forecast at -$116,361,279.

What is IMAB's revenue growth forecast for 2028-2030?

(NASDAQ: IMAB) I Mab's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.

I Mab's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast IMAB's revenue for 2028 to be $4,260,324,264, with the lowest IMAB revenue forecast at $4,260,324,264, and the highest IMAB revenue forecast at $4,260,324,264. On average, 3 Wall Street analysts forecast IMAB's revenue for 2029 to be $9,413,064,470, with the lowest IMAB revenue forecast at $3,224,333,518, and the highest IMAB revenue forecast at $16,738,570,050.

In 2030, IMAB is forecast to generate $25,181,894,632 in revenue, with the lowest revenue forecast at $11,484,107,565 and the highest revenue forecast at $50,717,940,447.

What is IMAB's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: IMAB) forecast ROA is -68.27%, which is lower than the forecast US Biotechnology industry average of 44.43%.

What is IMAB's Price Target?

According to 3 Wall Street analysts that have issued a 1 year IMAB price target, the average IMAB price target is $6.33, with the highest IMAB stock price forecast at $7.00 and the lowest IMAB stock price forecast at $5.00.

On average, Wall Street analysts predict that I Mab's share price could reach $6.33 by Jul 9, 2026. The average I Mab stock price prediction forecasts a potential upside of 197.32% from the current IMAB share price of $2.13.

What is IMAB's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: IMAB) I Mab's current Earnings Per Share (EPS) is -$0.12. On average, analysts forecast that IMAB's EPS will be -$0.44 for 2025, with the lowest EPS forecast at -$0.61, and the highest EPS forecast at -$0.32. On average, analysts forecast that IMAB's EPS will be -$0.73 for 2026, with the lowest EPS forecast at -$0.87, and the highest EPS forecast at -$0.65. In 2027, IMAB's EPS is forecast to hit -$0.78 (min: -$0.97, max: -$0.62).

What is IMAB's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: IMAB) forecast ROE is -71.91%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.